Home › Prostate Cancer › NCT06617481
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence
Who can join
Ages 18 and older · Men
Full eligibility criteria
Inclusion Criteria: * History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy. * An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5 Exclusion Criteria: * Patients who are planned to have an x-ray contrast agent or other PET radiotracer \& less than 24 hours prior to the flotufolastat F-18 PSMA-PET scan. * Patients currently receiving Androgen Deprivation Therapy (ADT).
About the study
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer.
The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
What is being tested
- 18F-rhPSMA-7.3 (Posluma) (drug)
Sponsor: AdventHealth · Participants: 30 · Started: Sep 20, 2024
Contact the study team
- AdventHealth AdventHealth Oncology Research · Phone: 407-303-2090
Official record on ClinicalTrials.gov — NCT06617481
Locations in the U.S.
| Florida | AdventHealth, Orlando |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.